We are seeking an Immunohistochemistry (IHC) Assay Development Scientist with industry experience in CLIA-certified IHC assay development and clinical sample testing to join our Translational Sciences group. In this role, the Scientist should have a background in cancer biology and desire to leverage biomarkers to treat specific patient populations. The successful candidate will work closely with the Translational Sciences team and senior management and have an opportunity to play a significant role in cancer therapy development.
The IHC Assay Development Scientist will be responsible for the set-up and operation of a brand-new histology laboratory for CLIA-level certification to evaluate several biomarkers by automated IHC and image scanning. The Scientist will work closely with the Translational Sciences team to build the CLIA-certified laboratory space and develop and validate CLIA IHC assays for use in patient selection for clinical trial enrollment. The Scientist will be expected to understand and perform all tasks required to bring manual IHC methods to automation on a Leica Bond-III (or comparable) stainer and validate the automated IHC assays for use in a CLIA laboratory setting. The Scientist will receive and prepare tissue specimens from clinical trials for biomarker analyses by pathologist review. Procedures include CLIA laboratory set-up, automated IHC assay development and validation, developing and following standard operating procedures, accessioning, tissue processing, microtomy and staining, maintaining accurate tissue and slide records, cleaning and maintaining instruments and work areas. Additional IHC assays for research use only studies for tumor immune profiling and evaluating novel biomarkers to support the clinical drug candidate mechanism of action may also be performed.
Vigeo provides a collegial work atmosphere, with benefits that include group health and dental insurance, 401K, and paid time off.
Experience & Qualifications
BS/MS with a background in cellular biology, biochemistry, or a related field
Completion of an accredited histotechnology program
ASCP Histotechnician certification
Familiarity with CLIA regulations regarding assay certification
Ability to implement IHC assays developed from R&D into a CLIA-regulated environment
At least 2 years of biopharmaceutical industry experience, with specific experience in immunohistochemistry assay development and tissue sectioning
Proficiency in experimental design and execution, data analysis and interpretation, and data presentation
Strong analysis and problem-solving skills
Attention to details are crucial
Highly motivated and interactive, with the ability to succeed in a fluid team environment to meet shifting timelines and achieve changing project goals
Excellent skills in organization, written and oral communication, multitasking, and working in a highly collaborative cross-functional research environment
Internal Number: HT1
About Vigeo Therapeutics
Vigeo Therapeutics is a clinical-stage biotech company dedicated to the discovery and development of innovative cancer therapies. Located in Cambridge, Massachusetts, we are led by an experienced team with proven industrial R&D expertise and successful drug development records. Vigeo is privately held and funded by venture capital investors.